OncoSELECT is the perfect solution to identify new therapeutic options for lung (NSCLC), colon, breast (ER+ or HER2+) cancer patients. It analyses the tumoral DNA circulating in the patient's blood and is thus ideal when it is difficult to get a solid biopsy from a patient or to monitor response to the treatment in a minimally invasive way.
OncoSELECT only screens the most relevant genes related to treatments,
targeting markers of resistance or sensitivity to targeted therapies as well as specific genes selected for each cancer type.
For more information, contact us at the following e-mail address : firstname.lastname@example.org